Novo Nordisk A/ S stock (DK0060534915): Diabetes and obesity leader navigates patent challenges

Novo Nordisk A/S maintains its position as a global leader in diabetes and obesity care, with blockbuster drugs like Ozempic and Wegovy driving substantial growth. The company reported strong demand for its GLP-1 receptor agonists in recent quarters, though it faces increasing competition from Eli Lilly and others. Shares of Novo Nordisk A/S (DK0060534915) traded at approximately 130.50 USD on Nasdaq on May 11, 2026, reflecting resilience amid market volatility, according to Yahoo Finance as of 05/11/2026.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

Novo Nordisk A/S: core business model

Novo Nordisk A/S focuses on chronic disease treatments, primarily diabetes, obesity, and rare blood disorders. Founded in 1923, the company pioneered insulin production and has evolved into a biotech powerhouse. Its business model centers on innovation in peptide-based therapies, with a strong emphasis on R&D investment, which stood at 14% of 2024 sales according to the annual report published March 2025 on Novo Nordisk IR as of 03/2025.

The firm operates through two main segments: Diabetes and Obesity Care, and Rare Disease. Diabetes and Obesity now account for over 80% of revenue, fueled by GLP-1 drugs. Novo Nordisk A/S benefits from a robust pipeline, including oral semaglutide and next-gen insulins, positioning it for sustained growth in high-prevalence markets like the US.

Main revenue and product drivers for Novo Nordisk A/S

Ozempic (semaglutide injection) and Wegovy (higher-dose semaglutide) are flagship products, generating combined sales exceeding $20 billion in 2025 per Q4 results released February 2026 via company filings as of 02/2026. These GLP-1 agonists treat type 2 diabetes and obesity, tapping into a US market projected to reach $100 billion by 2030.

Insulin products like Tresiba and NovoLog remain steady contributors, while the Rare Disease unit grows via haemophilia treatments such as NovoSeven. US sales represent about 50% of total revenue, making Novo Nordisk A/S a key player for American investors seeking healthcare exposure.

Industry trends and competitive position

The GLP-1 market is exploding due to obesity epidemics, with Novo Nordisk A/S holding roughly 55% global share alongside Eli Lilly's Mounjaro/Zepbound. Patent expirations loom around 2032, but Novo defends with next-gen candidates like CagriSema, in phase 3 trials as of Q1 2026 updates from Reuters as of 04/2026.

Competition intensifies from generics and multi-agonists, yet Novo's manufacturing scale and supply chain investments provide an edge. For US investors, its Nasdaq ADR (NVO) offers direct access to this high-growth sector amid rising demand for weight-loss therapies.

Why Novo Nordisk A/S matters for US investors

Listed as NVO on Nasdaq, Novo Nordisk A/S provides US retail investors with exposure to Europe's top healthcare stock. Over 50% of its revenue derives from the US, where obesity affects 42% of adults, driving Wegovy prescriptions. The ADR format simplifies trading without currency risk conversion.

Recent supply expansions in the US, including new facilities in North Carolina, underscore commitment to American markets, per 2025 annual report.

Conclusion

Novo Nordisk A/S stands at the forefront of diabetes and obesity innovation, with GLP-1 drugs powering revenue amid a competitive landscape. While supply constraints and rivals pose challenges, its pipeline and US market dominance offer long-term potential. Investors monitor upcoming earnings and trial data for direction on this key healthcare name.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.